Blue Water Vaccines to Present at The Universal Influenza Vaccines 2022 Conference in Oxford, United Kingdom
CINCINNATI, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (BWV or Blue Water Vaccines or the Company) a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today announced that scientists from its research partner, The University of Oxford, will present at The Universal Influenza Vaccines 2022 Conference in Oxford, United Kingdom on Monday, September 5th, 2022.
CINCINNATI, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”) a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today announced that scientists from its research partner, The University of Oxford, will present at The Universal Influenza Vaccines 2022 Conference in Oxford, United Kingdom on Monday, September 5th, 2022.
Sunetra Gupta, Ph.D., Professor of Theoretical Epidemiology at The University of Oxford and current member of the BWV Scientific Advisory Board, will present BWV’s approach to a universal influenza vaccine, BWV-101, containing epitopes of limited variability identified for influenza H1, H3, and influenza B. The Company is also developing a standalone H1 pre-pandemic vaccine containing epitopes of limited variability, BWV-102.
“We are honored for Dr. Gupta to present our technology to such an esteemed group of colleagues in Oxford, where it all began for Blue Water Vaccines in 2019,” said Joseph Hernandez, Chairman and Chief Executive Officer of Blue Water Vaccines. “There is an immense global need for a lasting, efficacious, influenza vaccine and we look forward to collaborating with all in attendance at such a dedicated event.”
In July 2019, the Company entered into an exclusive, global license agreement relating to the use of epitopes of limited variability for the development and commercialization of influenza vaccine candidates. In addition, BWV and Oxford entered into a Sponsored Research Agreement in December 2019, extended in May 2022, to fund research and optimization of epitopes of limited variability for influenza vaccine candidate development.
BWV’s management will be available during the conference for one-on-one meetings. Interested parties may request a one-on-one meeting at [email protected] or contact BWV at (513) 620-4101.
About Blue Water Vaccines
Blue Water Vaccines Inc. is a biopharmaceutical company focused on developing transformational vaccines to address significant health challenges globally. Headquartered in Cincinnati, OH, the company holds the rights to proprietary technology developed at the University of Oxford, Cincinnati Children's Hospital Medical Center, and St. Jude Children's Hospital. The company is developing a universal flu vaccine that will provide protection from all virulent strains in addition to licensing a novel norovirus (NoV) S&P nanoparticle versatile virus-like particle (VLP) vaccine platform from Cincinnati Children’s to develop vaccines for multiple infectious diseases, including norovirus/rotavirus and malaria, among others. Additionally, Blue Water Vaccines is developing a Streptococcus pneumoniae (pneumococcus) vaccine candidate, designed to specifically prevent the highly infectious middle ear infections, known as Acute Otitis Media (AOM), in children. For more information, visit www.bluewatervaccines.com.
Forward-Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on BWV’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the development of BWV’s vaccine candidates; the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; delays and uncertainties caused by the global COVID-19 pandemic; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any vaccine under development, there are significant risks in the development, regulatory approval and commercialization of new products. BWV does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in BWV’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed with the Securities and Exchange Commission (the “SEC”) on March 31, 2022, Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, filed with the SEC on August 15, 2022 and periodic reports filed with the SEC on or after the date thereof. All of BWV’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.
Media Contact Information:
Blue Water Media Relations
Telephone: (646) 942-5591
Email: [email protected]
Investor Contact Information:
Blue Water Investor Relations
Email: [email protected]
